Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Spesolimab in Healthy Japanese Male Volunteers
NCT03123094Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of spesolimab in generalized pustular psoriasis (GPP) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events up to 151 days. Started May 2017; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT03123094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123094.